Anemia Study in chronic kidney disease (CKD): Erythropoiesis via a Novel Prolyl hydroxylase inhibitor (PHI) Daprodustat-Blood Pressure (ASCEND-BP)

Trial Identifier: 205665
Sponsor: GlaxoSmithKline
Collaborator:
ERT
Q2 Solutions
Quintiles
HemoCue
Start Date: July 2017
Primary Completion Date: July 2020

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
United States, California La Mesa, California, United States, 91942
United States, Colorado Lakewood, Colorado, United States, 80228
United States, Florida Coral Gables, Florida, United States, 33134
United States, Florida DeLand, Florida, United States, 32720
United States, Florida Hollywood, Florida, United States, 33024
United States, Florida Miami, Florida, United States, 33133
United States, Florida Orlando, Florida, United States, 32809
United States, Illinois Chicago, Illinois, United States, 60643
United States, Minnesota Minneapolis, Minnesota, United States, 55404
United States, South Carolina Spartanburg, South Carolina, United States, 29301
United States, Texas San Antonio, Texas, United States, 78215